Literature DB >> 33220271

Atractylenolides, essential components of Atractylodes-based traditional herbal medicines: Antioxidant, anti-inflammatory and anticancer properties.

Christian Bailly1.   

Abstract

The rhizome of the plant Atractylodes macrocephala Koidz is the major constituent of the Traditional Chinese Medicine Baizhu, frequently used to treat gastro-intestinal diseases. Many traditional medicine prescriptions based on Baizhu and the similar preparation Cangzhu are used in China, Korea and Japan as Qi-booster. These preparations contain atractylenolides, a small group of sesquiterpenoids endowed with antioxidant and anti-inflammatory properties. Atractylenolides I, II and III also display significant anticancer properties, reviewed here. The capacity of AT-I/II/IIII to inhibit cell proliferation and to induce cancer cell death have been analyzed, together with their effects of angiogenesis, metastasis, cell differentiation and stemness. The immune-modulatory properties of ATs are discussed. AT-I has been tested clinically for the treatment of cancer-induced cachexia with encouraging results. ATs, alone or combined with cytotoxic drugs, could be useful to treat cancers or to reduce side effects of radio and chemotherapy. Several signaling pathways have been implicated in their multi-targeted mechanisms of action, in particular those involving the central regulators TLR4, NFκB and Nrf2. A drug-induced reduction of inflammatory cytokines production (TNFα, IL-6) also characterizes these molecules which are generally weakly cytotoxic and well tolerated in vivo. Inhibition of Janus kinases (notably JAK2 and JAK3 targeted by AT-I and AT-III, respectively) has been postulated. Information about their metabolism and toxicity are limited but the long-established traditional use of the Atractylodes and the diversity of anticancer effects reported with AT-I and AT-III should encourage further studies with these molecules and structurally related natural products.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atractylenolides; Cancer therapeutics; Natural products; Phytotherapy; Signaling pathways; Traditional medicine

Mesh:

Substances:

Year:  2020        PMID: 33220271     DOI: 10.1016/j.ejphar.2020.173735

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4.

Authors:  Ying Gao; Jundong Wang; Maoyuan Zhao; Ting Xia; Qingsong Liu; Nianzhi Chen; Wenhao Liao; Zhongzhen Zeng; Fengming You; Jinhao Zeng
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

2.  Network Pharmacology-Based Study of the Underlying Mechanisms of Huangqi Sijunzi Decoction for Alzheimer's Disease.

Authors:  Wei Zhang; Mingti Lv; Yating Shi; Yonghui Mu; Zhaoyang Yao; Zhijun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-05       Impact factor: 2.629

3.  Effect of the extract made from Rhizoma Atractylodis Macrocephalae (RAM) on the immune responses of mice to a commercial foot-and-mouth disease vaccine.

Authors:  Ming Qin; Jiewei Liu; Kedsirin Sakwiwatkul; Han Yan; Xiaoyu Chang; Shengbo Chi; Yutao Li; Ruili Li
Journal:  Vet Med Sci       Date:  2022-08-18

Review 4.  Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics.

Authors:  Mao Deng; Huijuan Chen; Jiaying Long; Jiawen Song; Long Xie; Xiaofang Li
Journal:  Arch Pharm Res       Date:  2021-07-16       Impact factor: 4.946

Review 5.  Dietary Supplements in Chemotherapy-Induced Peripheral Neuropathy: A New Hope?

Authors:  Katarzyna Szklener; Sebastian Szklener; Adam Michalski; Klaudia Żak; Weronika Kuryło; Konrad Rejdak; Sławomir Mańdziuk
Journal:  Nutrients       Date:  2022-01-31       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.